ASRS

ASRS 2020 coverage: Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD,on behalf of the DRCR Retina Network.

ASRS 2020 coverage: Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting. Faricimab is a bispecific antibody that simultaneously inhibits angiopoietin-2 and vascular endothelial growth factor A.

ASRS 2020 coverage: An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

ASRS 2020 coverage: Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

ICYMI: Dr. Blinder compares the efficiencies between two surgical cutters

Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial

Annual meeting schedule to include presentations, live surgery, awards

Beyond the sessions, this year’s conference offers multiple events for attendees.